The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.
Source link
About The Author
Merck has reached a nearly $6 billion cash deal to buy the cancer biotech Terns Pharmaceuticals and its promising leukemia treatment